Precigen, Inc. EV/Operating CF

EV/Operating CF of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/Operating CF of Precigen, Inc. is -24.9 (as of December 30, 2020)
  • EV/Operating CF for the quarter ending September 29, 2021 was -18.7 (a -19.58% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -24.9%
  • Annual EV/Operating CF for 2020 was -24.9 (a 242.64% increase from previous year)
  • Annual EV/Operating CF for 2019 was -7.27 (a 8.07% increase from previous year)
  • Annual EV/Operating CF for 2018 was -6.72 (a -54.81% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of Precigen, Inc.

Most recent EV/Operating CFof PGEN including historical data for past 10 years.

Interactive Chart of EV/Operating CF of Precigen, Inc.

Precigen, Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -18.7 -23.25 -21.66
2020 -24.9 -7.42 -9.01 -5.12 -24.9
2019 -7.27 -7.16 -8.73 -6.19 -7.27
2018 -6.72 -16.76 -14.94 -16.6 -6.72
2017 -14.88 -25.64 -33.78 -30.73 -14.88
2016 -54.93 -158.42 53.78 82.23 -54.93
2015 87.44 235.33 -114.44 -109.54 87.44
2014 -132.17 -82.91 -76.45 -78.12 -132.17
2013 -14.88 -19.56 -0.23 -0.23 -14.88
2012 -0.23 -0.23 -0.23
2011 -0.23

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.